{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

Insulin-Related Medications

Insulin-Related Medications - Medication Exenatide Insulin...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Medication Brand Name Medication Class FDA Indication MOA Eff of plasma [Glu] Eff on Insulin Eff on C-Peptide Exenatide Byetta Incretin mimetics Tx of DM II in pts not responsive to metformin, sulfonylureas, thiazolidinedione, or combo therapy GLP-1 agonist; mimics action of incretins binding to GLP-1 receptor. Binding to GLP-1 receptor-->increase in glucose-dep synthesis of insulin, and increase in secretion of insulin from beta-cells in presence of elevated insulin Indirectly lowers plasma glucose by increasing GLP-1 mediate insulin secretion. Leads to a release in insulin only in the presence of elevated glucose concentrations Increase? Insulin N/A DM Type I, insulin-dependent pts Direct agonist of IR on target cells. Increase GLUT4 exocyotosis on skeletal muscle cells, increasing Glucose uptake. Inhibits hepatic glucose production (glygenolysis and gluconeogenesis) Decrease N/A None? (does not increase endogenous insulin secretion) Metformin Glucophage biguanide DM II, monotherapy or combo Tx
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}